CClinicalTrials.gg
CompletedNCT03286101Updated Mar 7, 2018

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

A Phase 2 interventional study of 0.5% Ivermectin lotion and Vehicle in Pediculosis Capitis, sponsored by United Laboratories. Completed at 1 site in Philippines. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by United Laboratories · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.

02

Conditions studied

  • Pediculosis Capitis

Browse trials for

03

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled.
  • Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free).
  • Subject is male or female;
  • Subject is at least 3 years old or older at the time of enrollment;
  • Subject is in good general health based on the medical history;
  • Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation.
  • Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product.
  • Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study;
  • Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed;
  • Subject agrees to not cut or chemically treat their hair while participating in the study;
  • Subject agrees to follow all study instructions.

Exclusion criteria

Exclusion Criteria:

  • History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products;
  • Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations;
  • Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study;
  • Treatment for head lice (OTC, home remedy or Rx) in the last 14 days;
  • Subjects under treatment which in the opinion of the investigator will interfere with the study results;
  • Subjects who participated in a previous investigational drug study within the past 30 days;
  • Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator;
  • Females who are pregnant or lactating.
  • Living in a household where at least one member is pregnant, lactating, or planning a pregnancy
  • Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    0.5% Ivermectin Lotion

    Drug: 0.5% Ivermectin lotion

  • Placebo comparator
    Vehicle control

    Drug: Vehicle

Interventions

  • Drug0.5% Ivermectin lotion

    The intervention is composed of a single application of the 0.5% ivermectin lotion.

  • DrugVehicle

    The intervention is composed of a single application of the vehicle control.

05

What researchers measure

Primary outcomes

  1. Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.

    Time frame: Day 2 to day 15 after product application

06

Study locations

1 site
  • Clinical Trial Management and Testing Associates, Inc.
    Muntinlupa, Philippines
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03286101
Lead sponsor
United Laboratories
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Sep 14, 2017
Primary completion
Oct 12, 2017
Completion
Nov 9, 2017
Last update
Mar 7, 2018

Study contacts

Gertrude Chan, M.D.
principal investigator · Clinical Trial Management and Testing Associates, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion